Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Amarin’s AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and S…

April 17, 2011 By Bio-Medicine.Org

MYSTIC, Conn. and DUBLIN, April 18, 2011 /PRNewswire/ — Amarin
Corporation plc (Nasdaq:
AMRN
), a clinical-stage biopharmaceutical company with a focus
on cardiovascular disease, today reported positive, statistically
significant top-line results from its ANCHOR trial for the
Company’s lead product candidate, AMR101. The Phase 3 trial met its
primary and secondary efficacy endpoints for both the 4 gram and 2
gram daily doses.

The purpose of the ANCHOR trial was to demonstrate that AMR101
is effective in reducing triglyceride levels in patients with high
triglycerides without increasing LDL-C (“bad cholesterol”) levels
in patients on background statin therapy. The ANCHOR trial
investigated AMR101 as a treatment for high triglycerides (≥200
and <500mg/dL) in 702 patients with mixed dyslipidemia (two or
more lipid disorders) on background statin therapy at LDL-C
(low-density lipoprotein cholesterol) goal who were at high risk of
cardiovascular disease. The majority of these patients were
diabetic (73%). This is the largest trial with omega-3 therapy
conducted in this important patient population. All patients were
on background statin therapy with simvastatin, atorvastatin or
rosuvastatin. Despite the benefits of statin therapy, patients in
this population have significant residual risk for cardiovascular
events. The trial’s primary endpoint was defined as the percentage
change in triglyceride levels from baseline compared to placebo
after twelve weeks of treatment. In addition, the study was powered
to demonstrate a lack of LDL-C elevating effect with AMR101
compared to placebo. The trial was conducted under a Special
Protocol Assessment (SPA) agreement with the FDA.

Triglyceride Reduction Levels Exceeded Company
Expectations

The primary endpoint for triglyceride change was achieved at
both 4 grams and 2 grams per day with median placebo-adjusted

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech